GI-4000

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
GI-4000
Accession Number
DB05698
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Description

A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity. 1

Synonyms
Not Available
External IDs
GI-4000
Categories
Not Available
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in pancreatic cancer.

Pharmacodynamics
Not Available
Mechanism of action

Upon administration, GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras. This may lead to a destruction of cancer cells expressing a Ras mutation.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Link [Link]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentMalignant Neoplasm of Pancreas1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas4
1, 2Active Not RecruitingTreatmentMCRC / Metastatic Colorectal Cancers1
1, 2Active Not RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2WithdrawnTreatmentCancer of the Ovary1
1, 2WithdrawnTreatmentColorectal Cancers1
1, 2WithdrawnTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2WithdrawnTreatmentHepatocellular Carcinoma Non-resectable / Recurrent Hepatocellular Carcinoma1
1, 2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2WithdrawnTreatmentTransitional Cell Carcinoma1
1, 2WithdrawnTreatmentTriple Negative Breast Cancer (TNBC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMalignant Neoplasm of Colon1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2WithdrawnTreatmentPancreatic Cancer Metastatic1
2WithdrawnTreatmentTriple Negative Breast Cancer (TNBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:27 / Updated on September 02, 2019 18:15